At the heart of European technology
At the heart of European technology
Invoke is a technology investment and advisory company focused on identifying world-leading technology emerging across Europe through the private sector and university channels. In addition to providing capital, we help entrepreneurs productise and bring their fundamental technologies to the market.

About Us

Dedicated to accelerating the growth of early-stage companies, our technological expertise and repositioning experience allow us to rapidly scale fundamental technologies across multiple markets. We are the only investment team in Europe with a dedicated, in-house R&D division, based in Cambridge, UK.

The Invoke team has grown multiple technology businesses. Our expertise and experience in science and technology allows us to identify and develop core technologies in areas including genomics, security, pattern recognition, signal processing and big data.

Our Network

Invoke has unique, well-established links with the European tech scene and unrivalled access to world-class science and engineering talent. We are connected to various major European universities and have a strong relationship with Cambridge University, including college fellowships and membership at Cambridge Enterprise, the University's commercial vehicle.

We also hold positions on science and industry governing bodies, such as Nesta, the Royal Academy of Engineering, the Foundation for Science and Technology and the Royal Society Development Board, as well as membership on UK Government advisory boards, including the Prime Ministerial Council for Science and Technology and the Tech City Investment Organisation.

The Team

Dr Mike Lynch OBE FREng FRS
Founder, Technology Entrepreneur

Mike is a celebrated technologist and has a proven track record of identifying and monetising fundamental technologies. Spun out from his previous company, Neurodynamics, which he sold in 2005, Mike founded Autonomy in 1996 based on technology invented at Cambridge University, where Dr Lynch studied Information Sciences, received a Ph.D. and held a research fellowship in adaptive pattern recognition. He served as CEO of Autonomy for over fifteen years, during which time it became one of the UK's most successful technology companies on the FTSE100. Autonomy was acquired by HP for $11 billion in 2011.

Mike is regarded as Britain's most successful technology entrepreneur and has won numerous awards, including Computer Weekly's 'Most Influential Person of the Year' and the Chartered Institute for IT's award for Outstanding Contribution to IT in 2011. He was awarded an OBE for Services to Enterprise in 2006. Mike is a fellow of the Royal Academy of Engineering, an honorary fellow of Christ's College Cambridge and a non-executive director of the British Library. He is also a scientific advisor to the UK Prime Minister. He was elected a Fellow of the Royal Society in April 2014.

Portfolio Investments

Darktrace

Darktrace is a cyber defense technology company, which offers a radically new approach to the challenge of cyber threats and attack, based on ground-breaking mathematics and deep operational intelligence expertise.

MORE »

The company was founded in early 2013 by Steve Huxter, who formerly held senior roles in the UK government's cyber defense policy unit, and Andrew France OBE, formerly Deputy Director of Cyber Operations at GCHQ, who joined forces with a group of world-class machine learning specialists and mathematicians at the University of Cambridge.

Darktrace is the leader in Enterprise Immune System technology, a new category of cyber defense solutions, which is uniquely capable of detecting emerging threats from within an organization. This ground-breaking technology adaptively analyzes the behavior of individuals and groups across entire networks, establishing a pattern of life for each entity and detecting behavioral anomalies in real time. Based on a key breakthrough in probabilistic mathematics at the University of Cambridge, Recursive Bayesian Estimation theory, Darktrace's solutions give organizations across the world the ability to detect suspicious activity as it manifests itself, giving them time to take meaningful defensive action.

In a new era of sophisticated and industrialized cyber threat, traditional approaches have failed to keep the threat out. Darktrace's new approach takes for granted that threat is always present, and takes into account the needs, knowledge and intentions of human users. The company's 'immune system' approach involves dynamically learning what is normal for each user and machine and spotting subtle human traces of activity, in order to spot true anomalies and detect 'unknown unknown' threats.

Darktrace's flagship, self-learning platform, Darktrace Cyber Intelligence Platform (DCIP), powered by Enterprise Immune System technology, is relied on to deliver the next generation of cyber defense to customers across a range of industry verticals, including telecommunications, financial services, transportation and energy and utilities.

The company is headquartered in Cambridge, UK, with offices in London, Milan, New York, Paris, San Francisco and Washington D.C.

Taggar, powered by Neurence

Taggar is the world's first mobile application to be built upon the Neurence platform and was released in December 2013. By using Neurence's highly advanced pattern-matching algorithms, Taggar supports the most advanced image recognition software to date on phones.

MORE »

Neurence is an intelligent recognition engine that sits in the cloud, which can handle image, audio and video data. Any device can stream information to Neurence, which then understands and recognizes it. Almost instantaneously, Neurence then brings back appropriate and useful information to each device — outsourcing the processing of information to Neurence and removing the need for infrastructure on the device itself.

By using Neurence, Taggar is able to provide the only social augmented reality platform, which allows users to create hidden worlds to share with friends and followers. The Taggar app recognizes the objects that it is looking at, and then reveals what content has been secretly tagged behind every object. Users can unlock every object's secret tags by scanning it with Taggar. Users can then tag their objects with their own personal content, leaving secret messages in the form of video, pictures and stickers.

By tapping into Neurence's cloud, Taggar's smartphone software allows for instantaneous image recognition of millions of objects. All content generated by users sits within the Neurence cloud, meaning that every tag is available to all users, instantly.

Because image-recognition occurs within Neurence's cloud, it is device-agnostic, and does not require much device processing power to run. Even a simple streaming camera can send imagery to the cloud and Neurence can recognize it and bring back information — it doesn't require infrastructure on the device itself. Likewise, Taggar is optimized to work with the next generation of devices, such as wearable technology like glasses.

By constantly communicating the camera feed to Neurence's cloud-based brain, phones running Neurence software can actually understand what they are looking at. Now, users need only to point their device towards the various objects around them to receive information on what they are looking at.

Sophia Genetics

Sophia Genetics is a pioneer in the nascent field of Data Driven Medicine, combining a deep expertise in genetics, bioinformatics, machine learning and genomic privacy.

MORE »

Founded in Lausanne, and with very close links to the machine learning hub in Cambridge, UK, Sophia Genetics has a fundamentally new approach to the development and clinical adoption of Data Driven Medicine, focused on achieving best patient outcomes whilst keeping patients' personal genomic data secure. Its software as a service (SaaS) offering, the Data Driven Medicine Platform, covers the bioinformatic analysis protocol, the validation and quality control process, the presentation of results of genetic tests to clinicians and the protection of patient DNA sequence data through safe storage and banking. Sophia Genetics has received ISO 13485 accreditation and is the first European company to obtain a CE-IVD mark for the clinical use of a Next Generation Sequencing (NGS) bioinformatic pipeline for routine genetic testing.

As patient and doctor demand for gene sequencing increases, the technologies to satisfy that demand need to scale, and to become embedded into laboratories' processes quickly. Sophia Genetics works with labs and hospitals across Europe, including Switzerland, France, UK, Turkey and Germany. It has offices in Lausanne, London and Cambridge.

Press

8 July 2014 — Sophia Genetics raises Series B round led by Invoke Capital Read more...

6 December 2013 — Invoke Capital invests in cloud-based recognition engine and the first social augmented reality app Read more...

17 October 2013 — Mike Lynch awarded the 2013 Global University Venturing Personality of the Year Award Read more...

16 September 2013 — Invoke Capital makes first investment in fundamental cyber security technology Read more...

Contact

General enquiries: [email protected]

Media enquiries: [email protected]

California
London & Cambridge
London
Invoke Capital
80 Pall Mall
London
SW1Y 5ES

Tel: +44 (0) 20 7839 6798
Cambridge
Invoke Capital HQ
21 JJ Thomson Avenue
Cambridge
CB3 0FA

Tel: +44 (0) 1223 324114
California
Invoke Capital
California



Tel: +1 949 637 2600